| Year |
Citation |
Score |
| 2023 |
Decaudin D, Dit Leitz EF, Nemati F, Tarin M, Naguez A, Zerara M, Marande B, Vivet-Noguer R, Halilovic E, Fabre C, Jochemsen A, Roman-Roman S, Alsafadi S. Corrigendum to "Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma" [Eur J Cancer 126 (2020) 93-103]. European Journal of Cancer (Oxford, England : 1990). PMID 36868971 DOI: 10.1016/j.ejca.2023.02.004 |
0.511 |
|
| 2021 |
Abdul Razak AR, Bauer S, Suarez C, Lin CC, Quek R, Hütter-Krönke ML, Cubedo R, Ferretti S, Guerreiro N, Jullion A, Orlando EJ, Clementi G, Sand Dejmek J, Halilovic E, Fabre C, et al. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34921024 DOI: 10.1158/1078-0432.CCR-21-1291 |
0.317 |
|
| 2020 |
Decaudin D, Frisch Dit Leitz E, Nemati F, Tarin M, Naguez A, Zerara M, Marande B, Vivet-Noguer R, Halilovic E, Fabre C, Jochemsen A, Roman-Roman S, Alsafadi S. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma. European Journal of Cancer (Oxford, England : 1990). 126: 93-103. PMID 31927215 DOI: 10.1016/j.ejca.2019.12.012 |
0.508 |
|
| 2019 |
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, et al. Correction: Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 2938. PMID 31043386 DOI: 10.1158/1078-0432.CCR-19-0959 |
0.343 |
|
| 2015 |
Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 20: 1666-7. PMID 26400497 DOI: 10.1007/S10495-015-1154-9 |
0.769 |
|
| 2014 |
Fabre C, Gobbi M, Ezzili C, Zoubir M, Sablin MP, Small K, Im E, Shinwari N, Zhang D, Zhou H, Le Tourneau C. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. Cancer Chemotherapy and Pharmacology. 74: 1057-64. PMID 25217392 DOI: 10.1007/s00280-014-2583-9 |
0.335 |
|
| 2013 |
Kaufman JL, Fabre C, Lonial S, Richardson PG. Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy. Clinical Lymphoma, Myeloma & Leukemia. 13: 370-6. PMID 23787122 DOI: 10.1016/j.clml.2013.03.016 |
0.328 |
|
| 2013 |
Cormier F, Monjanel H, Fabre C, Billot K, Sapharikas E, Chereau F, Bordereaux D, Molina TJ, Avet-Loiseau H, Baud V. Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. Plos One. 8: e59127. PMID 23555623 DOI: 10.1371/journal.pone.0059127 |
0.412 |
|
| 2012 |
Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG. New proteasome inhibitors in myeloma. Current Hematologic Malignancy Reports. 7: 258-66. PMID 23065395 DOI: 10.1007/s11899-012-0141-2 |
0.355 |
|
| 2012 |
Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, et al. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4669-81. PMID 22806876 DOI: 10.1158/1078-0432.Ccr-12-0779 |
0.356 |
|
| 2012 |
Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, et al. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma. Blood. 119: 5772-81. PMID 22538852 DOI: 10.1182/Blood-2011-07-366633 |
0.356 |
|
| 2011 |
Cirstea D, Hideshima T, Santo L, Eda H, Canavese M, Scullen TA, Mahindra AK, Gorgun G, Hu Y, Mimura N, Fabre C, Minami J, Ohguchi H, Anderson KC, Guichard SM, et al. DEPTOR Is a Regulator of Response to mTOR Kinase Inhibitors in Multiple Myeloma Blood. 118: 2916-2916. DOI: 10.1182/Blood.V118.21.2916.2916 |
0.418 |
|
| 2011 |
Fabre C, Mimura N, Bobb K, Gorgun G, Cirstea DD, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Mitsiades CS, Richardson PG, Hideshima T, Anderson KC. Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM) Blood. 118: 2902-2902. DOI: 10.1182/Blood.V118.21.2902.2902 |
0.437 |
|
| 2010 |
Mimura N, Hideshima T, Gorgun G, Cirstea D, Santo L, Hu Y, Fabre C, Blumenthal M, Tam V, Kertesz NL, Zeng Q, Patterson JB, Munshi NC, Richardson P, Anderson KC. Targeting IRE1α-XBP1 Pathway Is a Novel Therapeutic Strategy In Multiple Myeloma Blood. 116: 4074-4074. DOI: 10.1182/Blood.V116.21.4074.4074 |
0.375 |
|
| 2010 |
Gorgun G, Hideshima T, Mimura N, Cirstea D, Santo L, Hu Y, Fabre C, Raje N, Munshi NC, Richardson PG, Anderson KC. Inhibition of Histone Deacetylase 6 Effects on Interaction of Tumor and Immune Cells In Multiple Myeloma Blood. 116: 2996-2996. DOI: 10.1182/Blood.V116.21.2996.2996 |
0.328 |
|
| 2010 |
Santo L, Hideshima T, Cirstea D, Bandi ML, Nelson EA, Ikeda H, Vallet S, Pozzi S, Patel K, Gorgun G, Mimura N, Fabre C, Hu Y, Chauhan D, Squires MS, et al. AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor with Potent Activity Against Aurora Kinase and STAT3 In Combination with Lenalidomide Results In Synergistic Anti-Myeloma Activity Blood. 116: 2994-2994. DOI: 10.1182/Blood.V116.21.2994.2994 |
0.469 |
|
| 2008 |
Grosjean-Raillard J, Tailler M, Adès L, Perfettini JL, Fabre C, Braun T, De Botton S, Fenaux P, Kroemer G. ATM mediates constitutive NF-kappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene. 28: 1099-109. PMID 19079347 DOI: 10.1038/Onc.2008.457 |
0.744 |
|
| 2008 |
Grosjean-Raillard J, Adès L, Boehrer S, Tailler M, Fabre C, Braun T, De Botton S, Israel A, Fenaux P, Kroemer G. Flt3 receptor inhibition reduces constitutive NFkappaB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia. Apoptosis : An International Journal On Programmed Cell Death. 13: 1148-61. PMID 18670883 DOI: 10.1007/s10495-008-0243-4 |
0.769 |
|
| 2008 |
Fabre C, Grosjean J, Tailler M, Boehrer S, Adès L, Perfettini JL, de Botton S, Fenaux P, Kroemer G. A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle (Georgetown, Tex.). 7: 2139-45. PMID 18641459 DOI: 10.4161/Cc.7.14.6268 |
0.744 |
|
| 2008 |
Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood. 111: 2170-80. PMID 17925489 DOI: 10.1182/Blood-2007-07-100362 |
0.741 |
|
| 2007 |
Braun T, Carvalho G, Grosjean J, Ades L, Fabre C, Boehrer S, Debili N, Fenaux P, Kroemer G. Differentiating megakaryocytes in myelodysplastic syndromes succumb to mitochondrial derangement without caspase activation. Apoptosis : An International Journal On Programmed Cell Death. 12: 1101-8. PMID 17245643 DOI: 10.1007/S10495-006-0030-Z |
0.625 |
|
| 2007 |
Boehrer S, Ades L, Braun T, Galluzzi L, Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, Fenaux P, Kroemer G. The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML. Blood. 110: 399-399. DOI: 10.1182/Blood.V110.11.399.399 |
0.753 |
|
| 2007 |
Ades L, Boehrer S, Braun T, Grosjean J, Fabre C, Fenaux P, Kroemer G. Disruption of Bcl-2 Heterodimerization by the BH3 Mimetic ABT-737 Restores Spontaneous Apoptosis and Induces Differentiation in High Risk MDS and AML. Blood. 110: 398-398. DOI: 10.1182/Blood.V110.11.398.398 |
0.586 |
|
| 2007 |
Boehrer S, Ades L, Galluzzi L, Olaussen K, Braun T, Grosjean J, Fabre C, de Botton S, Fenaux P, Kroemer G. Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways. Blood. 110: 2438-2438. DOI: 10.1182/Blood.V110.11.2438.2438 |
0.744 |
|
| 2007 |
Boehrer S, Adès L, Braun T, Grosjean J, Fabre C, Fenaux P, Kroemer G. P057 Abrogation of the DNA-damage response in AML versus MDS cell lines Leukemia Research. 31: S71. DOI: 10.1016/S0145-2126(07)70127-3 |
0.567 |
|
| 2007 |
Boehrer S, Adàs L, Braun T, Galluzzi L, Grosjean J, Fabre C, de Botton S, Gardin C, Fenaux P, Kroemer G. P039 The EGFR-inhibitor erlotinib exhibits various off-target effects in MDS and AML Leukemia Research. 31: S62. DOI: 10.1016/S0145-2126(07)70109-1 |
0.651 |
|
| 2006 |
Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologic malignancies. Cell Death and Differentiation. 13: 748-58. PMID 16498458 DOI: 10.1038/Sj.Cdd.4401874 |
0.636 |
|
| 2006 |
Boehrer S, Ades L, Fabre C, Fenaux P, Kroemer G. The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM). Blood. 108: 856-856. DOI: 10.1182/Blood.V108.11.856.856 |
0.618 |
|
| 2006 |
Boehrer S, Ades L, Fabre C, Fenaux P, Kroemer G. Abrogation of the DNA-Damage Response in De Novo AML Versus MDS Cell Lines. Blood. 108: 2649-2649. DOI: 10.1182/Blood.V108.11.2649.2649 |
0.525 |
|
| 2005 |
Gonzalez-Polo RA, Carvalho G, Braun T, Decaudin D, Fabre C, Larochette N, Perfettini JL, Djavaheri-Mergny M, Youlyouz-Marfak I, Codogno P, Raphael M, Feuillard J, Kroemer G. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene. 24: 7503-13. PMID 16091749 DOI: 10.1038/Sj.Onc.1208907 |
0.713 |
|
| 2004 |
Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Müller S, Jaffrézou JP, Laurent G. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood. 104: 1166-73. PMID 15126316 DOI: 10.1182/Blood-2004-01-0277 |
0.457 |
|
| Show low-probability matches. |